ID   SW13
AC   CVCL_0542
SY   SW-13; SW 13; Scott and White No. 13
DR   CLO; CLO_0009185
DR   CLO; CLO_0009209
DR   MCCL; MCC:0000444
DR   CLDB; cl4435
DR   CLDB; cl4436
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-3610
DR   ATCC; CCL-105
DR   BCRC; 60483
DR   BCRJ; 0300
DR   BioSample; SAMN03472418
DR   BioSample; SAMN03472692
DR   cancercelllines; CVCL_0542
DR   CCRID; 1101HUM-PUMC000055
DR   CCRID; 3101HUMTCHu221
DR   Cell_Model_Passport; SIDM00814
DR   ChEMBL-Cells; CHEMBL3308467
DR   ChEMBL-Targets; CHEMBL1075587
DR   CLS; 300349
DR   Cosmic; 684683
DR   Cosmic; 909744
DR   Cosmic; 1024274
DR   Cosmic; 1179077
DR   Cosmic; 1622872
DR   Cosmic; 2239456
DR   Cosmic-CLP; 909744
DR   DepMap; ACH-001401
DR   ECACC; 87031801
DR   EGA; EGAS00001000978
DR   GDSC; 909744
DR   GEO; GSM827353
DR   GEO; GSM1670498
DR   IARC_TP53; 2946
DR   IZSLER; BS TCL 62
DR   JCRB; JCRB9069
DR   KCB; KCB 200780YJ
DR   KCLB; 10105
DR   LINCS_LDP; LCL-1676
DR   PharmacoDB; SW13_1529_2019
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_0542
DR   PubChem_Cell_line; CVCL_0542
DR   TOKU-E; 3228
DR   Wikidata; Q54971076
RX   CelloPub=CLPUB00337;
RX   DOI=10.1007/978-1-4757-1647-4_2;
RX   PubMed=327080;
RX   PubMed=833871;
RX   PubMed=924690;
RX   PubMed=1516062;
RX   PubMed=3518877;
RX   PubMed=6244232;
RX   PubMed=6988327;
RX   PubMed=7459858;
RX   PubMed=11414198;
RX   PubMed=20164919;
RX   PubMed=20215515;
RX   PubMed=21924324;
RX   PubMed=22266826;
RX   PubMed=27397505;
RX   PubMed=30894373;
RX   PubMed=35839778;
WW   http://www.cells-talk.com/index.php/page/copelibrary?key=SW-13
WW   https://www.thermofisher.com/ch/en/home/technical-resources/cell-lines/s/cell-lines-detail-332.html
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   From: Scott and White Clinic; Temple; USA.
CC   Population: Caucasian.
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Mutation; HGNC; 11100; SMARCA4; Simple; p.Gln164Ter (c.490C>T); ClinVar=VCV001436624; Zygosity=Heterozygous (Cosmic-CLP=909744; DepMap=ACH-001401).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His193Tyr (c.577C>T); ClinVar=VCV000230256; Zygosity=Homozygous (ATCC=CCL-105; Cosmic-CLP=909744; DepMap=ACH-001401).
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Genome ancestry: African=2.01%; Native American=0%; East Asian, North=0%; East Asian, South=0.61%; South Asian=0.44%; European, North=72.28%; European, South=24.66% (PubMed=30894373).
CC   Derived from site: In situ; Adrenal gland; UBERON=UBERON_0002369.
ST   Source(s): ATCC=CCL-105; CCRID; CLS=300349; Cosmic-CLP=909744; DepMap=ACH-001401; ECACC=87031801; IZSLER=BS TCL 62; JCRB=JCRB9069; KCLB=10105
ST   Amelogenin: X
ST   CSF1PO: 11,12 (ATCC=CCL-105; Cosmic-CLP=909744; DepMap=ACH-001401; KCLB=10105)
ST   CSF1PO: 12 (CCRID; CLS=300349; ECACC=87031801; IZSLER=BS TCL 62; JCRB=JCRB9069)
ST   D13S317: 9
ST   D16S539: 12
ST   D18S51: 17
ST   D19S433: 14,15
ST   D21S11: 31,32.2
ST   D2S1338: 19,20
ST   D3S1358: 16
ST   D5S818: 11,12 (CCRID; CLS=300349; DepMap=ACH-001401; IZSLER=BS TCL 62; JCRB=JCRB9069; KCLB=10105)
ST   D5S818: 12 (ATCC=CCL-105; Cosmic-CLP=909744; ECACC=87031801)
ST   D7S820: 8,10
ST   D8S1179: 10
ST   FGA: 20
ST   Penta D: 10,13
ST   Penta E: 7,15
ST   TH01: 7 (JCRB=JCRB9069)
ST   TH01: 7,8 (ATCC=CCL-105; CCRID; CLS=300349; Cosmic-CLP=909744; DepMap=ACH-001401; ECACC=87031801; IZSLER=BS TCL 62; KCLB=10105)
ST   TPOX: 8
ST   vWA: 17,19
DI   NCIt; C9325; Adrenal cortex carcinoma
DI   ORDO; Orphanet_1501; Adrenocortical carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   55Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 02-05-24; Version: 43
//
RX   CelloPub=CLPUB00337;
RA   Leibovitz A., McCombs W.B. 3rd, Johnston D., McCoy C.E., Stinson J.C.;
RT   "Two new human cancer cell lines.";
RL   In Vitro 8:433-434(1973).
//
RX   DOI=10.1007/978-1-4757-1647-4_2;
RA   Leibovitz A.;
RT   "Development of media for isolation and cultivation of human cancer
RT   cells.";
RL   (In book chapter) Human tumor cells in vitro; Fogh J. (eds.); pp.23-50; Springer; New York; USA (1975).
//
RX   PubMed=327080; DOI=10.1093/jnci/59.1.221;
RA   Fogh J., Fogh J.M., Orfeo T.;
RT   "One hundred and twenty-seven cultured human tumor cell lines
RT   producing tumors in nude mice.";
RL   J. Natl. Cancer Inst. 59:221-226(1977).
//
RX   PubMed=833871; DOI=10.1093/jnci/58.2.209;
RA   Fogh J., Wright W.C., Loveless J.D.;
RT   "Absence of HeLa cell contamination in 169 cell lines derived from
RT   human tumors.";
RL   J. Natl. Cancer Inst. 58:209-214(1977).
//
RX   PubMed=924690; DOI=10.1002/ijc.2910200505;
RA   Kerbel R.S., Pross H.F., Leibovitz A.;
RT   "Analysis of established human carcinoma cell lines for
RT   lymphoreticular-associated membrane receptors.";
RL   Int. J. Cancer 20:673-679(1977).
//
RX   PubMed=1516062;
RA   Yoshimoto K., Iwahana H., Fukuda A., Sano T., Saito S., Itakura M.;
RT   "Role of p53 mutations in endocrine tumorigenesis: mutation detection
RT   by polymerase chain reaction-single strand conformation
RT   polymorphism.";
RL   Cancer Res. 52:5061-5064(1992).
//
RX   PubMed=3518877; DOI=10.3109/07357908609038260;
RA   Fogh J.;
RT   "Human tumor lines for cancer research.";
RL   Cancer Invest. 4:157-184(1986).
//
RX   PubMed=6244232;
RA   Williams R.D.;
RT   "Human urologic cancer cell lines.";
RL   Invest. Urol. 17:359-363(1980).
//
RX   PubMed=6988327; DOI=10.1007/BF02831503;
RA   O'Brien S.J., Shannon J.E., Gail M.H.;
RT   "A molecular approach to the identification and individualization of
RT   human and animal cells in culture: isozyme and allozyme genetic
RT   signatures.";
RL   In Vitro 16:119-135(1980).
//
RX   PubMed=7459858;
RA   Rousset M., Zweibaum A., Fogh J.;
RT   "Presence of glycogen and growth-related variations in 58 cultured
RT   human tumor cell lines of various tissue origins.";
RL   Cancer Res. 41:1165-1170(1981).
//
RX   PubMed=11414198; DOI=10.1007/s004320000207;
RA   Lahm H., Andre S., Hoeflich A., Fischer J.R., Sordat B., Kaltner H.,
RA   Wolf E., Gabius H.-J.;
RT   "Comprehensive galectin fingerprinting in a panel of 61 human tumor
RT   cell lines by RT-PCR and its implications for diagnostic and
RT   therapeutic procedures.";
RL   J. Cancer Res. Clin. Oncol. 127:375-386(2001).
//
RX   PubMed=20164919; DOI=10.1038/nature08768; PMCID=PMC3145113;
RA   Bignell G.R., Greenman C.D., Davies H.R., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458; PMCID=PMC2881662;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=21924324; DOI=10.1016/j.mce.2011.08.041; PMCID=PMC3288152;
RA   Wang T., Rainey W.E.;
RT   "Human adrenocortical carcinoma cell lines.";
RL   Mol. Cell. Endocrinol. 351:58-65(2012).
//
RX   PubMed=22266826; DOI=10.1055/s-0031-1298019; PMCID=PMC4269336;
RA   Wang T., Rowland J.G., Parmar J., Nesterova M., Seki T., Rainey W.E.;
RT   "Comparison of aldosterone production among human adrenocortical cell
RT   lines.";
RL   Horm. Metab. Res. 44:245-250(2012).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017; PMCID=PMC4967469;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747; PMCID=PMC6445675;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010; PMCID=PMC9387775;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//